Navigation Links
GeneGo Announces Systems Tox Relationship With Entelos
Date:3/17/2009

ST. JOSEPH, Mich., March 17 /PRNewswire/ -- GeneGo, Inc., the leading provider of pathway data mining & analysis solutions, today announced a license agreement with Entelos of Foster City, CA, a company specializing in predictive technologies, including toxicogenomics and PhysioLab(R) virtual human disease models. GeneGo will use Entelos' DrugMatrix(R) gene expression data to further develop GeneGo's Functional Descriptor predictive toxicology models.

"Access to a comprehensive, pharmacologically-diverse and fully annotated compendium of gene expression data is critical to developing high-performance predictive models," said Richard Brennan, Director of Toxicology at GeneGo. "This is one of the key goals of our MetaTox partnership. DrugMatrix is the largest toxicogenomic database available, and will allow us to apply the lessons we have learned from our participation in the Microarray Quality Control Consortium to expand our collection of biological pathway-based classifiers with toxicity models for a wide variety of adverse drug effects in key target tissues."

"We are very pleased to be working with GeneGo and participating in their MetaTox projects," said Alan Roter, VP of Informatics at Entelos. "GeneGo's unique approach of generating functional descriptors is a great complement to the classifiers and predictive models in DrugMatrix, and we see great benefit to the scientific community using predictive toxicogenomics."

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.2(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.2(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com.

About Entelos, Inc.

Entelos, Inc. is a US-based life sciences company applying next-generation predictive technologies to revolutionize the way medicines are discovered, developed, and utilized. The Company leverages its proprietary in silico disease models, "virtual human" technology, and toxicology reference systems to develop safer and more effective drugs, improve the quality of health-related consumer products, and deliver on the promise of personalized medicine. Entelos provides customized products, technology and research services to global pharmaceutical, health-care, and consumer products companies in safety testing, arthritis, cardiovascular diseases, asthma, obesity, diabetes, hematopoeisis (anemia), cholesterol metabolism, skin sensitization, and personal care products.

For more information, please visit the company's web site at www.entelos.com


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
2. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
3. Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation
4. GeneGo Integrates With Cytoscape
5. UC Berkeley Expands Molecular Toxicology Curriculum to Include GeneGos Platform
6. GSK Extends GeneGo License and Adds New Products
7. GeneGo Collaborates With The Netherlands Toxicogenomics Center on $100 Million Grant
8. VTT Technical Research Centre of Finland Licenses MetaCore from GeneGo for Cancer Research and Diagnostics
9. Unilever Extends Their GeneGo MetaCore License
10. Yale Keck Microarray Center Becomes a GeneGo Center of Excellence
11. University of Miami Miller School of Medicine Becomes a GeneGo Center of Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former senior ... the University of North Carolina Kenan-Flagler Business School effective June 27. ... Kenan-Flagler, with a focus on the school’s international efforts, leading classes and participating ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, into ... for over 35 years, is proud to add Target to its list of ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
Breaking Biology Technology:
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
Breaking Biology News(10 mins):